Mercado europeo de medicamentos inyectables estériles de moléculas pequeñas, por producto (llenado de viales, llenado de jeringas, llenado de cartuchos y otros), aplicación (oncología, enfermedades infecciosas, enfermedades cardiovasculares, enfermedades metabólicas, neurología, dermatología, urología, enfermedades autoinmunes, trastornos respiratorios y otros), usuarios finales (hospitales, clínicas especializadas, entornos de atención domiciliaria y otros), canales de distribución (licitación directa, farmacia minorista, farmacia en línea y otros), país (Alemania, Reino Unido, Francia, Italia, España, Países Bajos, Rusia, Suiza, Turquía, Bélgica, Suecia, Dinamarca, Polonia, resto de Europa), tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado : mercado europeo de medicamentos inyectables estériles de moléculas pequeñas
Se espera que el mercado de medicamentos inyectables estériles de moléculas pequeñas gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 6,8% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 60.229,99 millones para 2028. Se espera que la creciente prevalencia de enfermedades crónicas impulse el crecimiento del mercado de medicamentos inyectables estériles de moléculas pequeñas.
La administración de medicamentos inyectables es un proceso que implica la administración de un medicamento o una combinación de medicamentos en el cuerpo del paciente mediante el uso de diversos dispositivos de administración, como jeringas y agujas. Los medicamentos inyectables estériles se preparan con frecuencia en forma líquida debido a la facilidad de transporte de los medicamentos directamente en la circulación sanguínea sistémica. A veces, pueden prepararse para transportar los medicamentos a una parte específica del cuerpo.
El crecimiento de los medicamentos inyectables genéricos está impulsando el crecimiento del mercado de medicamentos inyectables estériles de moléculas pequeñas. El aumento de los retiros de productos está frenando el crecimiento del mercado de medicamentos inyectables estériles de moléculas pequeñas. El aumento del gasto en atención médica está actuando como una oportunidad para el crecimiento del mercado de medicamentos inyectables estériles de moléculas pequeñas. La falta de accesibilidad es un desafío para el mercado de medicamentos inyectables estériles de moléculas pequeñas.
El informe de mercado de medicamentos inyectables estériles de moléculas pequeñas proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado de medicamentos inyectables estériles de moléculas pequeñas, comuníquese con Data Bridge Market Research para obtener un informe de analista; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de medicamentos inyectables estériles de moléculas pequeñas
El mercado de medicamentos inyectables estériles de moléculas pequeñas está segmentado en función del producto, la aplicación, los usuarios finales y los canales de distribución. El crecimiento entre segmentos le ayuda a analizar nichos de crecimiento y estrategias para abordar el mercado y determinar sus áreas de aplicación principales y la diferencia en sus mercados objetivo.
- En función del producto, el mercado de medicamentos inyectables estériles de moléculas pequeñas se segmenta en llenado de viales, llenado de jeringas , llenado de cartuchos y otros. En 2021, se espera que el segmento de llenado de viales domine el mercado de medicamentos inyectables estériles de moléculas pequeñas debido al creciente avance tecnológico en medicamentos inyectables estériles de moléculas pequeñas.
- En función de la aplicación, el mercado de medicamentos inyectables estériles de moléculas pequeñas se segmenta en oncología, enfermedades infecciosas , enfermedades cardiovasculares, enfermedades metabólicas, neurología, dermatología , urología, enfermedades autoinmunes, trastornos respiratorios y otros. En 2021, se espera que el segmento de oncología domine el mercado de medicamentos inyectables estériles de moléculas pequeñas debido al creciente número de pacientes que padecen cáncer.
- En función de los usuarios finales, el mercado de medicamentos inyectables estériles de moléculas pequeñas se segmenta en hospitales , clínicas especializadas, entornos de atención domiciliaria y otros. En 2021, se espera que el segmento de hospitales domine el mercado de medicamentos inyectables estériles de moléculas pequeñas debido al creciente número de hospitales en los países en desarrollo.
- Sobre la base de los canales de distribución, el mercado de medicamentos inyectables estériles de moléculas pequeñas se segmenta en licitación directa, farmacia minorista, farmacia en línea y otros. En 2021, se espera que el segmento de licitación directa domine el mercado de medicamentos inyectables estériles de moléculas pequeñas porque la opción de licitación directa es utilizada principalmente por los hospitales de canal grande para comprar productos inyectables estériles de moléculas pequeñas.
Análisis a nivel de país del mercado de medicamentos inyectables estériles de moléculas pequeñas en Europa
El mercado europeo de medicamentos inyectables estériles de moléculas pequeñas está segmentado según el producto, la aplicación, los usuarios finales y los canales de distribución.
Los países cubiertos en el informe del mercado de medicamentos inyectables estériles de moléculas pequeñas de Europa son Alemania, Reino Unido, Francia, Italia, España, Países Bajos, Rusia, Suiza, Turquía, Bélgica, Suecia, Dinamarca, Polonia y el resto de Europa.
Se espera que el segmento de llenado de viales en Alemania domine el mercado europeo de medicamentos inyectables estériles de moléculas pequeñas debido a los crecientes avances tecnológicos.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Small Molecule Sterile Injectable Drugs is boosting the Small Molecule Sterile Injectable Drugs Market Growth
The small molecule sterile injectable drugs market also provides you with detailed market analysis for every country growth in small molecule sterile injectable drugs market. Additionally, it provides the detail information regarding the small molecule sterile injectable drugs market players’ strategy and their geographical presence. The data is available for historic period 2010 to 2019.
Competitive Landscape and Small Molecule Sterile Injectable Drugs Market Share Analysis
The small molecule sterile injectable drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Europe small molecule sterile injectable drugs market.
The major companies which are dealing in the Europe small molecule sterile injectable drugs market report are Gilead Sciences, Inc., BIOCRYST PHARMACEUTICALS, INC., AstraZeneca, Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Hikma Pharmaceuticals PLC, AbbVie Inc., American Regent, Inc. (a Daiichii Sankyo Group Company), Amgen Inc., Bristol- Myers Squibb Company, Teligent, Eisai Co., Ltd., Teva Pharmaceutical Industries Ltd., Neuren Pharmaceuticals, Amomed Pharma GmbH, Sanofi, Exelixis, Inc., Fresenius Kabi USA (a subsidiary of Fresenius SE & Co. KGaA), Pfizer Inc. among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contracts and agreements are also initiated by the companies’ worldwide which are also accelerating the small molecule sterile injectable drugs market.
For instance,
- In May 2020, AbbVie Inc. acquired Allergan, a global company focused on manufacturing products targeting neuroscience, urology among other medical fields. This acquisition allowed the company to enhance its therapeutic categories and strengthen the company's financial values, which ultimately accelerated the company's research and developmental activities.
Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market players is enhancing the company footprints in the small molecule sterile injectable drugs market which also provides the benefit for organization’s profit growth.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S ANALYSIS
5 REGULATORY FRAMEWORK
5.1 REGULATORY GUIDANCE AS PER U.S. FDA.
5.2 REGULATORY SCENARIO FOR EUROPEAN UNION
5.3 REGULATORY SCENARIO IN JAPAN
5.4 REGULATORY FRAMEWORK IN CHINA
6 PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES
7.1.2 PRODUCT APPROVAL OF SMALL MOLECULE
7.1.3 HIGH R&D INVESTMENT FOR SMALL MOLECULE DEVELOPEMNT
7.1.4 STRONG PIPELINE FOR SMALL MOLECULE INJECTABLE
7.1.5 GROWTH IN GENERIC INJECTABLES
7.2 RESTRAINTS
7.2.1 HIGH LEVEL OF QUALITY AND CARE REQUIRED IN THE PRODUCTION
7.2.2 HIGH MANUFACTURING AND PURCHASING COST OF INJECTABLES
7.2.3 STRINGENT REGULATIONS FOR FACILITES AND EQUIPMENTS REQUIRED FOR SMALL MOLECULES INJECTABLE
7.2.4 PRODUCT RECALL
7.3 OPPORTUNITIES
7.3.1 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
7.3.2 GROWING PRODUCT LAUNCHES
7.3.3 RISING PER CAPTIA INCOME AND HEALTHCARE EXPENDITURE
7.4 CHALLENGES
7.4.1 LACK OF ACCESSIBILITY
7.4.2 HIGH COST OF DIAGNOSIS & TREATMENT
8 IMPACT OF COVID-19 ON THE EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET
8.1 OVERVIEW AFTERMATH OF COVID-19 AND GOVERNMENT ROLE
8.2 IMPACT ON PRICE
8.3 IMPACT ON DEMAND
8.4 IMPACT ON SUPPLY CHAIN
8.5 STRATEGIC DECISIONS OF GOVERNMENT AND MANUFACTURERS
8.6 CONCLUSION
9 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 VIAL FILLING
9.3 SYRINGE FILLING
9.4 CARTRIDGE FILLING
9.5 OTHERS
10 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 ONCOLOGY
10.3 INFECTIOUS DISEASES
10.4 CARDIOVASCULAR DISEASES
10.5 METABOLIC DISEASES
10.6 NEUROLOGY
10.7 UROLOGY
10.8 DERMATOLOGY
10.9 AUTOIMMUNE DISEASES
10.1 RESPIRATORY DISORDERS
10.11 OTHERS
11 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 SPECIALTY CLINICS
11.4 HOMECARE SETTING
11.5 OTHERS
12 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL PHARMACY
12.4 ONLINE PHARMACY
12.5 OTHERS
13 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 FRANCE
13.1.3 U.K.
13.1.4 ITALY
13.1.5 SPAIN
13.1.6 NETHERLANDS
13.1.7 RUSSIA
13.1.8 SWITZERLAND
13.1.9 BELGIUM
13.1.10 TURKEY
13.1.11 SWEDEN
13.1.12 DENMARK
13.1.13 POLAND
13.1.14 REST OF EUROPE
14 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 PFIZER INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 SERVICE PORTFOLIO
16.2 GILEAD SCIENCES, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 FRESENIUS KABI USA (ASUBSIDIARY OF FRESENIUS SE & CO. KGAA).
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 ABBVIE INC.
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 AMERICAN REGENT, INC. (A DAIICHI SANKYO GROUP COMPANY)
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 AMGEN INC.
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENTS
16.8 AMOMED PHARMA GMBH
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 ASTRAZENECA
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.1 BIOCRYST PHARMACEUTICALS, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENTS
16.11 BRISTOL-MYERS SQUIBB COMPANY
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENTS
16.12 EISAI CO., LTD.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
16.13 EXELIXIS, INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 REVENUE ANALYSIS
16.13.3 PRODUCT PORTFOLIO
16.13.4 RECENT DEVELOPMENT
16.14 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 HIKMA PHARMACEUTICALS PLC
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENTS
16.17 NEUREN PHARMACEUTICALS
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 NOXOPHARM
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 SANOFI
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT
16.2 TELIGENT
16.20.1 COMPANY SNAPSHOT
16.20.2 REVENUE ANALYSIS
16.20.3 PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Lista de Tablas
TABLE 1 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, PIPELINE ANALYSIS
TABLE 2 NUMBER OF PEOPLE WITH DIABETES (MILLION) AMONG AGES 20–79 YEARS
TABLE 3 PER CAPITA AMOUNTS: UNITED STATES (1960–2017 YEARS)
TABLE 4 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 5 EUROPE VIAL FILLING IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 EUROPE SYRINGE FILLING IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 EUROPE CARTRIDGE FILLING IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 EUROPE OTHERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 9 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 10 EUROPE ONCOLOGY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 EUROPE INFECTIOUS DISEASES IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 12 EUROPE CARDIOVASCULAR DISEASE IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 EUROPE METABOLIC DISEASES IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 EUROPE NEUROLOGY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 EUROPE UROLOGY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 EUROPE DERMATOLOGY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 EUROPE AUTOIMMUNE DISEASES IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 EUROPE RESPIRATORY DISORDERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 EUROPE OTHERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 21 EUROPE HOSPITALS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 22 EUROPE SPECIALTY CLINICS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 EUROPE HOMECARE SETTING IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 24 EUROPE OTHERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 26 EUROPE DIRECT TENDER IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 EUROPE RETAIL PHARMACY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 EUROPE ONLINE PHARMACY IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 EUROPE OTHERS IN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 31 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 32 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 33 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 34 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 35 GERMANY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 36 GERMANY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 37 GERMANY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 38 GERMANY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 39 FRANCE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 40 FRANCE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 41 FRANCE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 42 FRANCE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 43 U.K. SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 44 U.K. SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 45 U.K. SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 U.K. SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 47 ITALY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 48 ITALY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 49 ITALY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 50 ITALY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 51 SPAIN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 52 SPAIN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 53 SPAIN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 SPAIN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 NETHERLANDS SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 56 NETHERLANDS SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 57 NETHERLANDS SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 58 NETHERLANDS SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 59 RUSSIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 60 RUSSIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 61 RUSSIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 RUSSIA SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 63 SWITZERLAND SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 64 SWITZERLAND SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 65 SWITZERLAND SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 66 SWITZERLAND SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 67 BELGIUM SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 68 BELGIUM SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 69 BELGIUM SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 70 BELGIUM SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 71 TURKEY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 72 TURKEY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 73 TURKEY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 74 TURKEY SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 75 SWEDEN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 76 SWEDEN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 77 SWEDEN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 78 SWEDEN SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 79 DENMARK SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 80 DENMARK SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 81 DENMARK SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 82 DENMARK SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 83 POLAND SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
TABLE 84 POLAND SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 85 POLAND SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 86 POLAND SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 87 REST OF EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET, BY PRODUCT, 2019-2028 (USD MILLION)
Lista de figuras
FIGURE 1 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 2 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: EUROPE VS. REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: PRODUCT LIFELINE CURVE
FIGURE 8 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 9 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 10 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 12 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 13 THE GROWING GERIATRIC POPULATION IS EXPECTED TO DRIVE THE EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 PRODUCT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGE OF EUROPE IMMUNOASSAYS-GAMMA COUNTER MARKET
FIGURE 16 THE GRAPH BELOW SHOWS THE INCREASING PREVALENCE OF CHRONIC DISEASES IN 1995 TO FORECAST 2030 IN THE U.S.
FIGURE 17 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, 2020
FIGURE 18 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, 2021-2028 (USD MILLION)
FIGURE 19 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, CAGR (2021-2028)
FIGURE 20 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 21 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, 2020
FIGURE 22 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 23 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 24 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 25 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, 2020
FIGURE 26 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 27 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 28 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 30 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 31 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 32 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 33 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: SNAPSHOT (2020)
FIGURE 34 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY COUNTRY (2020)
FIGURE 35 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 36 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 37 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: BY PRODUCT (2021-2028)
FIGURE 38 EUROPE SMALL MOLECULE STERILE INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
